Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
about
PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like culturesPituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAEThe VPAC1 receptor: structure and function of a class B GPCR prototype.Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancerSignificance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis.Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor.PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.Impaired extinction of cued fear memory and abnormal dendritic morphology in the prelimbic and infralimbic cortices in VPAC2 receptor (VIPR2)-deficient mice.High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons.Vasoactive Intestinal peptide modulates c-Fos activity in the trigeminal nucleus and dura mater mast cells in sympathectomized rats.Identification of Dysregulated microRNA Networks in Schwann Cell-Like Cultures Exposed to Immune Challenge: Potential Crosstalk with the Protective VIP/PACAP Neuropeptide System.PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.The Neuropeptides Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Control HIV-1 Infection in Macrophages Through Activation of Protein Kinases A and C.
P2860
Q28543252-2E7AA806-5D23-49D7-B9DD-C303F28F83C9Q34684150-209018F3-7F4D-4B09-AC27-4C2C3786CFA9Q36403782-A7CA27EF-BFC7-42FB-9DC9-95D5F31C746FQ36834005-94FDB87B-92F8-4BFD-B6AC-4CF378391C26Q38344541-D3D60AF5-691A-4726-9819-EB2C87356C32Q38694548-2E910E86-BB26-426F-AF31-78AB58F34298Q41769727-7A3A022E-20D3-442F-8BA3-DC84972E4403Q42516817-DC7DAFBF-2FAA-4050-9AB5-6E40EA48FCBAQ46214035-6F9F3464-8394-4A74-8066-F7B0C9ACB196Q48423560-7D1376C6-D322-477C-A2D4-1AD546121612Q51731153-571BFADD-BC5C-4E6E-89ED-326FE7D2AEC6Q52656846-51189A5A-0C17-41A0-A0DA-8396C88E2402Q55486269-547E4134-795D-4BA3-8A71-6310067457FF
P2860
Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@ast
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@en
type
label
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@ast
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@en
prefLabel
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@ast
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@en
P2860
P921
P356
P1433
P1476
Targeting VIP and PACAP recept ...... ategies in multiple sclerosis.
@en
P2093
James A Waschek
Yossan-Var Tan
P275
P2860
P356
10.1042/AN20110024
P5008
P577
2011-10-06T00:00:00Z